These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14631624)

  • 1. Cyclosporin A-associated status epilepticus related to hematopoietic stem cell transplantation for thalassemia.
    Zakrzewski JL
    Pediatr Hematol Oncol; 2003 Sep; 20(6):481-6. PubMed ID: 14631624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
    Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
    Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
    Khojasteh HN; Zakerinia M; Ramzi M; Haghshenas M
    East Mediterr Health J; 1999 May; 5(3):465-9. PubMed ID: 10793825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
    Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
    Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus.
    Takahata M; Hashino S; Izumiyama K; Chiba K; Suzuki S; Asaka M
    Bone Marrow Transplant; 2001 Oct; 28(7):713-5. PubMed ID: 11704797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of hematopoietic progenitor cells in thalassemia after bone marrow transplantation.
    Tang-naitrisorana Y; Issaragrisil S; Visuthisakchai S; Suvatte V; Piankijakum A
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():291-5. PubMed ID: 8629127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible cortical blindness and convulsions with cyclosporin A toxicity in a patient undergoing allogeneic peripheral stem cell transplantation.
    Madan B; Schey SA
    Bone Marrow Transplant; 1997 Nov; 20(9):793-5. PubMed ID: 9384485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myelodysplastic syndrome with cyclosporine A-induced encephalopathy presenting with a mass effect on the right basal ganglia after cord blood transplantation].
    Koh H; Yamane T; Nakane T; Takeoka Y; Sakamoto E; Kanashima H; Nakamae M; Nakamae H; Koh KR; Mochizuki K; Hayashi N; Hino M
    Rinsho Ketsueki; 2006 Dec; 47(12):1539-43. PubMed ID: 17233473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.